GLP Watchdog

GoodRx vs LifeMD

Neither GoodRx nor LifeMD has an FDA warning letter on record. On brand-name tirzepatide pen, GoodRx costs $1,788 less a year at standing rates: $299 a month against $448 a month at LifeMD.

To see where both sit among the other sellers, read our best weight-loss injection providers board.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

GoodRx / LifeMD

GoodRx logo

GoodRx

7.8/10

LifeMD logo

LifeMD

6.0/10

FDA warning letters
None on record
None on record
Pharmacy
Brand-name only; no compounding
Brand-name only; no compounding
Lowest standing price
$149/moFoundayo (orforglipron) pill
$298/moBrand-name semaglutide pill
States
48 states
All 50 states
Checked
Prices captured Record checked October 2026
Prices captured Record checked October 2026
Visit GoodRx
Visit LifeMD

Neither GoodRx nor LifeMD pays us. Links to them earn nothing. Scores: GoodRx 7.8, LifeMD 6.0. How we are paid

What the record shows

  1. 01

    Neither GoodRx nor LifeMD has an FDA warning letter on record.

  2. 02

    On brand-name tirzepatide pen, GoodRx costs $1,788 less a year at standing rates: $299 a month against $448 a month at LifeMD.

  3. 03

    Only GoodRx lists a price for Foundayo (orforglipron) pill. Only LifeMD lists a price for brand-name semaglutide pen and brand-name semaglutide pill.

  4. 04

    LifeMD covers two states GoodRx does not.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

GoodRx

LifeMD

Brand-name tirzepatide pen

$299/moLower

$3,588 a year

$448/mo

$5,376 a year

Brand-name semaglutide pen
Not sold or not priced

$348/mo

$4,176 a year

Brand-name semaglutide pill
Not sold or not priced

$298/mo

$3,576 a year

Foundayo (orforglipron) pill

$149/mo

$1,788 a year

Not sold or not priced
Price includes
Not stated
Clinician visits, labs, coaching
Billed separately
Not stated
Medication
Cancel any time
Yes, stated
Yes, stated
Minimum term
None
None
Refunds
Services and medication are generally non-refundable
Money-back guarantee after 12 months if under 10% loss and all conditions met

Read off each seller’s own pages. GoodRx: October 30, 2026. LifeMD: October 31, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for GoodRx

7.8/10
  • $1,788 a year less on brand-name tirzepatide pen
  • Sells Foundayo (orforglipron) pill, which LifeMD does not price
Visit GoodRx

The case for LifeMD

6.0/10
  • Sells brand-name semaglutide pen and brand-name semaglutide pill, which GoodRx does not price
  • Price leaves out medication
Visit LifeMD

Scores

GoodRx 7.8 · LifeMD 6.0 out of 10. Six weighted parts.

Value25%

8.7A
vs
B
3.0

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

5.0A
vs
B
3.0

Trust & Safety15%

6.0A
vs
B
5.0

Accessibility10%

9.7A
vs
B
10.0

Support10%

5.0A
vs
B
5.5

The score is the same formula for every seller. Payment does not enter it. Method

GoodRx vs LifeMD: questions

Neither GoodRx nor LifeMD has an FDA warning letter on record. Letters are matched to a seller by company, domain and address, never by a similar name.
GoodRx, by $1,788 a year at standing rates. GoodRx: $299 a month, about $3,588 a year. LifeMD: $448 a month, about $5,376 a year.
GoodRx states you can cancel at any time; refunds: services and medication are generally non-refundable. LifeMD states you can cancel at any time; refunds: money-back guarantee after 12 months if under 10% loss and all conditions met.
Neither GoodRx nor LifeMD pays us. Links to them earn nothing. Scores: GoodRx 7.8, LifeMD 6.0.

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Sellers closest to these two

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks